• Home
  • About
    • Overview
    • Sharing Data
    • ORCID
  • Help
  • History (1)
    • MGMT-inhibitor in combination with TGF-?RI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
    • See All Pages
  • search
    • Find People
    • Find Everything
Login to edit your profile (add a photo, awards, links to other websites, etc.)
  • Edit My Profile
  • My Person List (0)

MGMT-inhibitor in combination with TGF-?RI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.

MGMT-inhibitor in combination with TGF-?RI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. Clin Transl Oncol. 2021 Mar; 23(3):612-619.

View in: PubMed

subject areas
  • Aminopyridines
  • Antineoplastic Agents, Alkylating
  • Antineoplastic Combined Chemotherapy Protocols
  • Astrocytes
  • Benzimidazoles
  • Brain Neoplasms
  • Cell Cycle
  • Cell Survival
  • Cells, Cultured
  • Cyclin D
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase 6
  • DNA Modification Methylases
  • DNA Repair Enzymes
  • Drug Resistance, Neoplasm
  • G1 Phase Cell Cycle Checkpoints
  • Glioblastoma
  • Guanine
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Neurons
  • Phosphatidylinositol 3-Kinases
  • Pyrazoles
  • Quinolines
  • Smad Proteins
  • Tumor Suppressor Proteins

authors with profiles
  • Arabinda Das
  • William Alexander Vandergrift
  • David Maria Cachia
  • Libby Kosnik Infinger